Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation

被引:78
|
作者
Chan, C. Stanley [1 ]
Van Voorhees, Abby S. [2 ]
Lebwohl, Mark G. [3 ]
Korman, Neil J. [5 ,6 ]
Young, Melodic
Bebo, Bruce F., Jr.
Kalb, Robert E. [4 ]
Hsu, Sylvia [1 ]
机构
[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA
[5] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Murdough Family Ctr Psoriasis, Cleveland, OH 44106 USA
关键词
CLOBETASOL PROPIONATE FOAM; TAZAROTENE 0.1-PERCENT GEL; PLAQUE PSORIASIS; CALCIPOTRIOL SOLUTION; BETAMETHASONE; 17-VALERATE; DOVOBET(R) OINTMENT; CLINICAL-EVALUATION; DOUBLE-BLIND; COAL-TAR; EFFICACY;
D O I
10.1016/j.jaad.2008.11.890
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The scalp is the most commonly affected part of the body in patients with psoriasis. Signs and symptoms of scalp psoriasis vary significantly for individual patients. Objective. A task force of the National Psoriasis Foundation was convened to evaluate treatment options. Our aim was to achieve a consensus for scalp psoriasis therapy. Methods: Reports in the medical literature were reviewed regarding scalp psoriasis therapy. Limitations: There is a paucity of evidence-based and double-blind Studies in the treatment of scalp psoriasis particularly for long-term therapy. Many of the studies in scalp psoriasis were designed to attain Food and Drug Administration approval for a medication and not to provide treatment guidance. Conclusions: The recommended short-term or intermittent therapy for scalp psoriasis is topical corticosteroids. The primary alternatives are topical retinoids, vitamin D analogues, and salicylic acid. Combination therapy has many advantages. The choice of an appropriate vehicle is crucial to increase patient compliance. While scalp psoriasis can often be adequately treated With topical therapy, recalcitrant disease may require more aggressive approaches, including systemic agents. (J Am Acad Dermatol 2009;60:962-71.)
引用
收藏
页码:962 / 971
页数:10
相关论文
共 50 条
  • [41] Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp
    Wang, Yao
    Coyne, Karin
    Sofen, Howard
    Santanello, Nancy
    Currie, Brooke
    Zhang, Zuoshun
    Nograles, Kristine
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (08) : 775 - 783
  • [42] Ustekinumab and TNF-inhibitors in the treatment of moderate to severe psoriasis
    Garcia Lopez, Isabel
    Herranz Alonso, Ana
    Rodriguez Gonzalez, Carmen Guadelupe
    Castillo Romera, Isabel
    Pernia Lopez, Sagrario
    Sanjurjo Saez, M.
    EJHP PRACTICE, 2011, 17 (01): : 46 - 50
  • [43] Efalizumab for the treatment of moderate to severe plaque psoriasis
    Jordan, JK
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1476 - 1482
  • [44] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [45] Xamiol®, a new treatment in scalp psoriasis: short- and long-term results
    Cambazard, F.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2009, 136 : S46 - S50
  • [46] Update on risankizumab for the treatment of moderate to severe psoriasis
    Al-Janabi, A.
    Warren, R. B.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1245 - 1251
  • [47] A new treatment in scalp psoriasis: Xamiol® formulation and results at 8 weeks
    Combemale, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2009, 136 : S42 - S45
  • [48] The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis
    Rajabi-Estarabadi, Ali
    Hasanzadeh, Hournaz
    Taheri, Arash
    Feldman, Steven R.
    Firooz, Alireza
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (02) : 111 - 115
  • [49] Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
    Singh, Jasvinder A.
    Guyatt, Gordon
    Ogdie, Alexis
    Gladman, Dafna D.
    Deal, Chad
    Deodhar, Atul
    Dubreuil, Maureen
    Dunham, Jonathan
    Husni, M. Elaine
    Kenny, Sarah
    Kwan-Morley, Jennifer
    Lin, Janice
    Marchetta, Paula
    Mease, Philip J.
    Merola, Joseph F.
    Miner, Julie
    Ritchlin, Christopher T.
    Siaton, Bernadette
    Smith, Benjamin J.
    Van Voorhees, Abby S.
    Jonsson, Anna Helena
    Shah, Amit Aakash
    Sullivan, Nancy
    Turgunbaev, Marat
    Coates, Laura C.
    Gottlieb, Alice
    Magrey, Marina
    Nowell, W. Benjamin
    Orbai, Ana-Maria
    Reddy, Soumya M.
    Scher, Jose U.
    Siegel, Evan
    Siegel, Michael
    Walsh, Jessica A.
    Turner, Amy S.
    Reston, James
    ARTHRITIS CARE & RESEARCH, 2019, 71 (01) : 2 - 29
  • [50] Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
    Singh, Jasvinder A.
    Guyatt, Gordon
    Ogdie, Alexis
    Gladman, Dafna D.
    Deal, Chad
    Deodhar, Atul
    Dubreuil, Maureen
    Dunham, Jonathan
    Husni, M. Elaine
    Kenny, Sarah
    Kwan-Morley, Jennifer
    Lin, Janice
    Marchetta, Paula
    Mease, Philip J.
    Merola, Joseph F.
    Miner, Julie
    Ritchlin, Christopher T.
    Siaton, Bernadette
    Smith, Benjamin J.
    Van Voorhees, Abby S.
    Jonsson, Anna Helena
    Shah, Amit Aakash
    Sullivan, Nancy
    Turgunbaev, Marat
    Coates, Laura C.
    Gottlieb, Alice
    Magrey, Marina
    Nowell, W. Benjamin
    Orbai, Ana-Maria
    Reddy, Soumya M.
    Scher, Jose U.
    Siegel, Evan
    Siegel, Michael
    Walsh, Jessica A.
    Turner, Amy S.
    Reston, James
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (01) : 5 - 32